Date: 2012-01-12
Type of information: Collaboration agreement
Compound: discovery and early development studies
Company: Covance USA) Inserm Transfert (France) Inserm Transfert Initiative (France)
Therapeutic area:
Type agreement: collaboration
R&D
Action mechanism:
Disease:
Details: Covance, the French National Institute of Health and Medical Research (Inserm) subsidiary Inserm Transfert SA, and seed investment company Inserm Transfert Initiative have announced the signing of a four-year scientific collaboration agreement for research and development. Under terms of the agreement, Covance will conduct discovery and early development studies, using its global capabilities including those at its facilities in Porcheville, France, and Alnwick, United Kingdom, for projects managed by Inserm Transfert, the knowledge transfer company of Inserm, and pre-clinical studies for start-ups within Inserm Transfert Initiative's portfolio. These Inserm Transfert Initiative companies will also gain access to the extensive scientific, operational and program management expertise Covance provides across all areas of drug discovery and development. Covance experts will advise representatives from Inserm Transfert and Inserm Transfert Initiative to help select projects that will most benefit from Covance’s broad range of drug discovery and drug development capabilities.
Financial terms: Financial terms were not disclosed.
Latest news:
